Centessa Pharmaceuticals plc ADR [CNTA] stock is trading at $13.20, up 7.67%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CNTA shares have gain 5.94% over the last week, with a monthly amount glided 8.64%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] stock has seen the most recent analyst activity on May 08, 2025, when Chardan Capital Markets initiated its Buy rating and assigned the stock a price target of $30. Previously, Piper Sandler started tracking the stock with Overweight rating on March 31, 2025, and set its price target to $38. On January 07, 2025, TD Cowen initiated with a Buy rating. Morgan Stanley upgraded its rating to a Overweight and increased its price target to $26 on September 20, 2024. B. Riley Securities initiated its recommendation with a Buy and recommended $33 as its price target on September 19, 2024. Oppenheimer started tracking with a Outperform rating for this stock on July 18, 2024, and assigned it a price target of $14. In a note dated November 15, 2023, Jefferies upgraded an Buy rating on this stock and boosted its target price from $4 to $11.
Centessa Pharmaceuticals plc ADR [CNTA] stock has fluctuated between $7.75 and $19.09 over the past year. Currently, Wall Street analysts expect the stock to reach $21 within the next 12 months. Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] shares were valued at $13.20 at the most recent close of the market. An investor can expect a potential return of 59.09% based on the average CNTA price forecast.
Analyzing the CNTA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -0.57 and Total Capital is -0.39. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Centessa Pharmaceuticals plc ADR’s Current Ratio is 14.37. In addition, the Quick Ratio stands at 14.37 and the Cash Ratio stands at 4.34. Considering the valuation of this stock, the price to sales ratio is 117.06, the price to book ratio is 4.56.
Transactions by insiders
Recent insider trading involved SAHA SAURABH, Chief Executive Officer, that happened on May 20 ’25 when 55000.0 shares were sold. Officer, SAHA SAURABH completed a deal on May 20 ’25 to buy 55000.0 shares. Meanwhile, Director GOYAL ARJUN bought 0.42 million shares on May 16 ’25.
